Share Name Share Symbol Market Type Share ISIN Share Description
Amryt Pharma LSE:AMYT London Ordinary Share GB00BDD1LS57 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.025p +0.15% 16.875p 16.75p 17.00p 16.875p 16.85p 16.85p 185,813 14:45:51
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 11.4 -23.2 -10.4 - 36.59

Amryt Pharma Share Discussion Threads

Showing 3001 to 3021 of 3025 messages
Chat Pages: 121  120  119  118  117  116  115  114  113  112  111  110  Older
DateSubjectAuthorDiscuss
24/5/2018
20:19
There were good rises today for some AIM listed biotechs. Three figure in the list of the 25 best risers today. N4P was up 22%, FARN up 18% & EVG up 10.4%. They all rose today on no news. N4P has been strong this year rising to well over 30p earlier this year. FARN is a special case, dropping to 106p yesterday after the big fall earlier this month on the disappointing phase III trial result. EVG has also performed strongly this year. Perhaps AMYT might benefit in the coming days from this feel good factor today for biotechs? FINGERS CROSSED as usual. One thing I've learned over the years is you can't predict share prices. I live in hope that I'll show a profit on my T20. EDIT. Lower Bollinger Band is at 16.5p & the Upper Bollinger Band is at 17.6p. Is a rise up towards the Upper Bollinger Band on the cards? We'll see.
papillon
24/5/2018
19:16
@waterloo01 EMA has been flexible in the past regarding ultra-rare diseases, see how the Lojuxta license was gained with only partial profile. And as I keep saying, because there is already an approval for AP101 (Episalvan) it tips the balance because there is a known safety profile. If clinicians are offering even anecdotal evidence this is a similar route to the FDA 'real world evidence reporting' path in the 21st Century Cures Act, where evidence from clinicians for off-label prescribing can be used to bolster the case for an expansion to an existing MA.
jimbobtechstock
24/5/2018
19:11
All interesting stuff although I would say it's stretching it a bit to call some limited compassionate use an 'open trial'. Certainly by my understanding. More anecdotal evidence.
waterloo01
24/5/2018
18:57
Many thanks, sidam. This is from the final results RNS (issued on the 17/4/2018) for the year ending 31/12/2017: "Cash balances totalled €20.5m at 31 December 2017 (2016: €8.3m), with €10m undrawn from the European Investment Bank facility" Hence at the start of 2018 AMYT had 20.5m Euro's of cash with 10m undrawn from the EIB loan. That gives a total cash of 30.5m Euro's available for 2018 + 2019. So if, as you state, the cash burn will INCLUDE the Lojuxta gross profit AMYT will be short of around 4 to 5m Euro's by the end of 2019. Not a large amount of money.
papillon
24/5/2018
18:07
The open label study is the use of Ap101 in TENS. Management said that a doctor (I think female) was using imulan to treat her patients and asked if she could have some AP101. This has been supplied on compassionate grounds. It is open label because it is not blind and her patients are being treated, there is no placebo in a control group. I have not watched the UKIS, so I can not tell you if it is the same, but my description I hope is correct and therefore you can check for yourselves. The estimated Cash Burn should be the amount of cash utilised by the business. It will include all gross profit, all costs including any that are capitalised, capital expenditure and changes in working capital. So it should include all lojuxta costs. The company has some cash and the undrawn facility. However that is not enough to finance the cash outflow in 2019. So it will need to raise equity or cash before the accounts for 2018 are published or those accounts will have a going concern audit opinion. That said there are alternatives. AP101(eb) could be licenced for Japan. Earlier, management indicated they would prefer a higher upfront payment and lower royalties as this would mean less dilution. The amount of cash to be raised will depend on whether they can sell some rights and the timing of AP101(eb) marketing. If that were 2021 as per Davy, then another year’s cash would be needed. I know what I would like, assuming AP101 is successful. That would be an offer to shareholders of a convertible with a conversion price of say 25p. I think that would get away. Would reduce dilution and I would love the income in my pension fund and ISA. I hope I have answered all questions, but come back if you want to.
sidam
24/5/2018
17:31
Well there was either a rollover, or bed & ISA, of 59,241 shares @ 16.87p this afternoon.
papillon
24/5/2018
16:44
And €10m to undrawn from the EIB loan. As per the annual report there was a variation on the original terms of the loan to remove a dependency in the original loan agreement on AP102 trial starting in order to unlock the second tranche: New terms are (from latest annual report) "In October 2017, the terms of the second tranche of €5m were amended by the EIB so the Group has the option to draw this amount down any time it wishes. The Group had not drawn down this second tranche of €5m as at 31 December 2017. The third tranche is conditional on the primary clinical endpoints for the EASE Phase III clinical trials in the US or EU being achieved and therefore it can be concluded that the Phase III clinical trial has been successfully completed. " So can add €5m on top of the cash balance. Additionally I expect the delay or deprioritisation of AP102 may have a +ve effect on the cash burn. I'm not sure what the reasons are behind the delay but it makes sense if the company is now focusing on Episalvan that such a small company postpones AP102 for a while, especially as they now have the very interesting AP103. Also they have now acquired the som research conducted by Dr Harris over the last year as part of the court settlement so I assume they want to use that to direct any further updates to AP102 strategy.
jimbobtechstock
24/5/2018
16:31
Many thanks for an excellent, informative, post, sidam. It all sounds very positive!! AMYT had 20.3m Euro's at 31/12/2017. Shore estimate cash burn at 14.5m + 19.6m = 34.4m Euro's for 2018+2019 Davy estimate cash burn at 16.6m + 17.6m = 34.2m Euro's for 2018+2019 Revenue from Lojuxta for 2018 + 2019 could equal that cash burn for 2018+2019. of course there would be the cost of Lojuxta sales. Do you know, sidam, if Davy & Shore include the cost of Lojuxta sales in their cash burn figures? Even if they don't and you deduct 55% of Lojuxta sales revenue as the cost of sales in 2018+2019 AMYT might still have available cash at the end of 2019, though it would be a bit tight. Also I can't remember if AMYT have yet drawn down the 2nd 10m Euro tranche from the EIB loan. If they have yet to draw down that 10m Euro's AMYT will definitely have cash remaining by the end of 2019. Any thoughts on that, sidam? tia.
papillon
24/5/2018
16:11
sidam - thank you very much for taking time to contribute. As per Bermudashorts I'd be interested to hear about the Open Label studies - are these possibly the 'small scale proof of concept clinical trial' mentioned in the UKIS presentation (about 14:45 in https://www.youtube.com/watch?v=P7bId2bUDsk )? I know EMA has accommodated many orphans under 'exceptional circumstances' approval, but in the UKIS presentation it was made to sound like there was a way to launch under the PTW existing approval. I'm not familiar with how a 'proof of concept' trial could be used to augment the existing MA but it makes sense on a rational level if can show the conditions are similar to (or sub0-classes of) a PTW. (Incidentally I do feel that all the noise of late on the BBs, especially raking up the Aegerion situation and getting me researching the Harris case has detracted from proper discussion of the science and business - maybe even that's not accidental!)
jimbobtechstock
24/5/2018
15:28
sidam - thanks for taking time and trouble to post your thoughts. Just a quick question, what open label study for AP101 are you referring to?
bermudashorts
24/5/2018
11:59
Turning point for Amyrt, not sure what I said yesterday to upset pap so much but I can't see it warrants a slap, albeit virtual. Clearly touched a nerve though. Busted the double-act and posted some possibilities - not fact, and neither were they "conspiracy theory", just possibilities. Possibilities that there's a short trading play in action, possibly around the EASE trial and the delay announced in March, possibly combined with the end of the trading restrictions in April. And then possibly that Pap is short and needs to close up. And that made his blood boil! Too close to the truth, possibly, because I for one only find my blood boils when my proverbial is on the chopping block and the axe is falling!
jimbobtechstock
24/5/2018
11:38
I'm thinking of doing what you did Shotgun42. I'm seriously thinking of ceasing to post on this bb. Maybe even stop reading the AMYT bb's altogether? I've got JimbobTechstock filtered on here & the lse bb, plus Bronxville filtered on the lse bb for spiteful deramping. I was spitting blood yesterday after what JimbobTechstock posted. I wanted to grab hold of him and give him a right hander, but unfortunately he's safe behind his anonymity. Reading these bb's can make my blood boil, especially when you get conspiracy theorists like JimbobTechstock talking out of their ar*ses and making accusations without any proof whatsover just because it suits their agenda.
papillon
24/5/2018
11:12
Seen it all before, unfortunately. One man's conspiracy is another's bread and butter in this game. share price looking depressed and derampers out usually means only one thing but the market has been known to surprise from time to time. Interesting point made about Woldquant, Followed the Quantum Pharma/Clinigen deal and wq very active shorting in the run up. Also as noted IMM, which had a curious rerate about 6 months before readout. Wq shorts only declared in 2018 though. Worldquant responsible for around 5% of shorts in London by position count last time I checked so easy target, might not be them. In fact highly likely there's no significant short open, my experience these kind of plays tend to rely on bursts of shorting to kill momentum, supplemented of course by negative sentiment posted on boards like this! All the very best, SG42
shotgun42
24/5/2018
10:13
We could have a little double bottom about to form on the AMYT chart, alphabravo321 since the share price was at the current level at the start of May. If a double bottom does form (the share price would need to rise above 18p again for it to form) then a rise to 19p-20p could be on the cards. I could be clutching at straws. Only time will tell.
papillon
24/5/2018
10:07
JimbobTechstock24 May '18 - 09:37 - 2893 of 2894 (Filtered) JimbobTechstock24 May '18 - 09:39 - 2894 of 2894 (Filtered) >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> Unusually for me, alphabravo321, I splashed out last week buying £600 of AMYT shares on a T20. I thought the 17.30p support would hold and was hoping that we could soon get a rise up to the 20.3p resistance level so I could close around the middle of June with a nice little profit. It might still happen. The share price is still hovering just under that 17.3p support. I've set myself a stop loss and will sell if the share price drops below 16p and take the circa £100 loss on the chin. Hopefully it wont come to that.
papillon
24/5/2018
09:39
The AI trading angle BTW I think may have something to do with the string of smaller trades popping up from time to time here, for months now, as well as the odd spread at times (pushing buying into the lower half of the spread) as well as the odd patterns on stochastics and MACD, all of which can indicate something in play.
jimbobtechstock
24/5/2018
09:37
Amount of deramping, especially on LSE, would indicate that someone actively wants the negative message out there. Only unknown is whether it's a bitter individual, maybe back from RTO or before, or a shorter. Because few others would be motivated to keep posting like that. If it's a short there's nothing on the FCA register so it's either undeclared (overseas), hidden behind some form of single stock future or held by a MM. Whilst MM have exception for short reporting, up to about 10% each, I think, this only applies for "market making purposes" so they may have accidentally run short expecting Cathal Friel's sale to hit the free float. Alternatively it might be a play around the known EASE recruitment (I heard it was slow as early as December) maybe with the perfect storm approaching given the end of selling restrictions on RTO shareholders in April. The latter sounds to be World Quant territory, where junior traders have to pitch increasingly elaborate trading strategies that are supplemented with AI driven not only by market trading but also bulletin board posting etc. Have found with WQ in particular that those traders coming up with the strategy are then on a bonus depending on how lucrative the strategy is. Apparently they have been known to cheer on their strategy on BBs. Have a read about World Quant. Sure others are doing it but WQ were known to be active on IMM, another AIM biotech, prior to data readout with a declared short position. But as I said no declared position here - which may mean nothing as maybe a declared short is just one they wanted us to see (on IMM). Eyes wide open. Not everything is as it seems.
jimbobtechstock
24/5/2018
08:22
Very tempting isn’t it??!!
bazworth
24/5/2018
08:14
Little top up for me on the lows...
alphabravo321
23/5/2018
18:24
JimbobTechstock 23 May '18 - 16:03 - 2888 of 2889 Clearly you just answered my unasked question as to whether you're a holder or not. Good luck sourcing the 4million shares you need. >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> DON'T BE SO SILLY. You know nothing about me! If you want to know more about me we can easily meet up. I live on the outskirts of Nottingham. I was a small FAST shareholder. I bought around 2p (equivalent to todays AMYT share price when they were effectively a cash shell selling at a significant discount to their cash) and have held AMYT since the RTO. I have held AMYT shares for a lot longer than you! I have been stating on this bb for the past 2 years that I would limit my exposure to AMYT to £5k (as far as I concerned it's a gamble as are all AIM shares). I've gone a bit over that and I might increase my limit to £6-£7k, especially if the share price drifts lower. I'm completely transparent when it comes to the shares I own. I recently bought small amounts of PVR & LOGP as a pure gamble. My investment is in hundreds of £'s only. I think you are a conspiracy theorist, JimbobTechstock. You're obviously a trader and I'm not in the same league as you. JimbobTechstock? FILTERED! You do some good research, but what you post has no effect on the share price Only a good RNS will do that. >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> PS. "Anyway, good luck to you. Deramping will kill sentiment a bit and help stem upwards momentum but at the end of it all you still have to close up" >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> I've never ramped, or deramped a share, unlike you. It's also a proud boast of mine that I've never been on Twitter, or Facebook. Basically, JimbobTechstock you are a deranged conspiracy theorist. I think you're deranged! I think you are MAD! You also, no doubt, unlike me, own an awful lot of AMYT shares bought at a far higher price than today's share price I can't help it if you're showing a big paper loss. I can't help it if you buy in terms of thousands of £'s rather than my hundreds of £'s. You're a nutter!
papillon
23/5/2018
16:14
Btw I've never held a share before where 3 separate IDs have contacted me to offer advice on AMYT. Pretty similar words used in one DM 'I've decided to take a break because I don't think it will move over summer, perhaps nearer to the interim readout' Same with a guy on AMYT twitter group. Won't move till Q4, apparently. I don't know who's running the show but looks to me like a trade based solely on the EB EASE trial progress, with shorts opened when it became known recruitment was slow (around Christmas I was told that, so sure the traders will have got wind if I'd heard) Whoever concocted this strategy overlooked Lojuxta and also the potential to launch Episalvan under existing MA. I know there could also have been a play to catch Cathatl's shares as low as possible but timing might suggest EASE as the main play. Anyway, good luck to you. Deramping will kill sentiment a bit and help stem upwards momentum but at the end of it all you still have to close up
jimbobtechstock
Chat Pages: 121  120  119  118  117  116  115  114  113  112  111  110  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20180525 01:35:47